News – Page 852 – Endpoints News

SIGN UP

Ex nihilo: Takeda leads $100M+ round to fund biotech's sneak attack on tumors, propelling new IL-2, CTLA-4 drugs to ...

6 years ago

The FDA OKs generic Daraprim, the Martin Shkreli therapy that triggered an unending tempest over drug pricing

6 years ago

Scoop: Corporate development chief hits the exit at Biogen as aducanumab jitters roll on

6 years ago

Why FDA can’t disclose the first coronavirus-related drug shortage

6 years ago

After the field left her behind, a scientist-turned-investor gets her first R&D job; Nouscom finds new leadership for ...

6 years ago

Sage confirms suspension of 2 depression trials after PhIII flop; Esperion follows up maiden approval with combo OK

6 years ago

Turning focus to clinical work, Verastem axes 31 jobs, scales back cancer drug promotion after disappointing sales

6 years ago

Ex-Sanofi chief Olivier Brandicourt, current Blackstone advisor, jumps on Alnylam board

6 years ago

Jim Wilson's gene therapy startup Passage Bio bucks market sentiments, raising upsized $216M IPO

6 years ago

A name emerges out of the Gilead M&A rumor mill, and it’s a cancer biotech

6 years ago

Biogen makes another bold Alzheimer’s bet, dropping $350M upfront to partner with genome-editing focused Sangamo

6 years ago

Biohaven scores CGRP OK for acute migraine — can the commercial team catch up with Allergan on its debut?

6 years ago

Another hiccup for GW Pharma's seizure drug rival, as Zogenix discloses FDA review delay

6 years ago

FDA taps chemoradio-sensitizing head and neck cancer drug as 'breakthrough'

6 years ago

A 9/11-era Omaha facility, an old Ebola drug, and the ubiquitous Dr. Fauci: Inside the first US novel coronavirus ...

6 years ago

Tessa gets RMAT designation for new CAR-T; FDA adcomm narrowly votes to expand Eli Lilly NSCLC label

6 years ago

UK follicular lymphoma patients set to get non-chemotherapy therapy as NICE backs Revlimid combo

6 years ago

Spark loses another top exec in the wake of $4.3B takeover by Roche — report

6 years ago

'The headlines are the headlines, but': BioMarin talks up potential savings as hemophilia gene therapy launch looms

6 years ago

Acacia Pharma's twice spurned drug finally makes the FDA cut

6 years ago

Following US, China hospital efforts, Gilead plots its own PhIII trials for closely watched Covid-19 drug

6 years ago

Scott Gottlieb in the running for possible coronavirus czar; The drug Vanda sued the FDA over fails a pivotal study

6 years ago

In at least one life-sci hub, gender and diversity initiatives haven’t made a dent

6 years ago

Will a 'risk-off' mindset hasten cell therapy M&A? Iovance surges on buyout chatter

6 years ago

First page Previous page 849 850 851852853 854 855 Next page Last page